Funding news
Editas Medicine logo

Editas Medicine Raises $120.0

Recently funded · $120.0M Series bHospitals and Health CareUSView source

Get the full Editas Medicine company profile

Access contacts, investors, buying signals & more

Open in Dashboard

Imagine a future where broken genes can be repaired. That's the ambitious premise behind Editas Medicine, the clinical stage genome editing company that has now raised $120.0M in Series b funding.

The company is focused on translating the power of CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments. This capital will support its goal to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of serious diseases.

Other United States companies recently funded

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
GRAIL logo

GRAIL

United States

$7.1B
4
Illumina logo

Illumina

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Series b rounds

Companies that recently closed a Series b round.

#CompanyAmount
1
Kushki logo

Kushki

Ecuador

$100.0M
2
Routable logo

Routable

United States

$500.0K
3
Robot.com logo

Robot.com

United States

$18.1M
4
Rapid Robotics, Inc logo

Rapid Robotics, Inc

United States

$36.7M
5
Infermedica logo

Infermedica

Poland

$30.0M